David J. Blanchard

Array ( [id] => 1124314 [patent_doc_number] => 06794494 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2004-09-21 [patent_title] => 'Cancerous disease modifying antibodies' [patent_app_type] => B1 [patent_app_number] => 10/413755 [patent_app_country] => US [patent_app_date] => 2003-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5350 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/794/06794494.pdf [firstpage_image] =>[orig_patent_app_number] => 10413755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7269876 [patent_doc_number] => 20040058394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-03-25 [patent_title] => 'Humanized anti-LT-beta-R antibodies' [patent_app_type] => new [patent_app_number] => 10/412406 [patent_app_country] => US [patent_app_date] => 2003-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10123 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0058/20040058394.pdf [firstpage_image] =>[orig_patent_app_number] => 10412406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 590748 [patent_doc_number] => 07435797 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2008-10-14 [patent_title] => 'Anti-HER2 antibody variants' [patent_app_type] => utility [patent_app_number] => 10/410894 [patent_app_country] => US [patent_app_date] => 2003-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 30880 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 12 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/435/07435797.pdf [firstpage_image] =>[orig_patent_app_number] => 10410894 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7399468 [patent_doc_number] => 20040023313 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-02-05 [patent_title] => 'Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors' [patent_app_type] => new [patent_app_number] => 10/408901 [patent_app_country] => US [patent_app_date] => 2003-04-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 26635 [patent_no_of_claims] => 73 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0023/20040023313.pdf [firstpage_image] =>[orig_patent_app_number] => 10408901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 968673 [patent_doc_number] => 06939948 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2005-09-06 [patent_title] => 'GD2 peptide mimics' [patent_app_type] => utility [patent_app_number] => 10/395434 [patent_app_country] => US [patent_app_date] => 2003-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5127 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/939/06939948.pdf [firstpage_image] =>[orig_patent_app_number] => 10395434 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7136104 [patent_doc_number] => 20040043970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-03-04 [patent_title] => 'Method for reducing psa levels' [patent_app_type] => new [patent_app_number] => 10/381225 [patent_app_country] => US [patent_app_date] => 2003-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3194 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0043/20040043970.pdf [firstpage_image] =>[orig_patent_app_number] => 10381225 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 443293 [patent_doc_number] => 07256273 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-08-14 [patent_title] => 'Humanized antibodies that recognize beta amyloid peptide' [patent_app_type] => utility [patent_app_number] => 10/388214 [patent_app_country] => US [patent_app_date] => 2003-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 20 [patent_no_of_words] => 29639 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/256/07256273.pdf [firstpage_image] =>[orig_patent_app_number] => 10388214 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7397904 [patent_doc_number] => 20040018557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-01-29 [patent_title] => 'Bispecific antibody point mutations for enhancing rate of clearance' [patent_app_type] => new [patent_app_number] => 10/377109 [patent_app_country] => US [patent_app_date] => 2003-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 19727 [patent_no_of_claims] => 67 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0018/20040018557.pdf [firstpage_image] =>[orig_patent_app_number] => 10377109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 464312 [patent_doc_number] => 07238785 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-07-03 [patent_title] => 'RS7 antibodies' [patent_app_type] => utility [patent_app_number] => 10/377121 [patent_app_country] => US [patent_app_date] => 2003-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 20 [patent_no_of_words] => 24828 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/238/07238785.pdf [firstpage_image] =>[orig_patent_app_number] => 10377121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6711008 [patent_doc_number] => 20030170757 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-11 [patent_title] => 'Monoclonal antibodies specific for neoplasia-specific NADH:disulfide reductase' [patent_app_type] => new [patent_app_number] => 10/373579 [patent_app_country] => US [patent_app_date] => 2003-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 12017 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0170/20030170757.pdf [firstpage_image] =>[orig_patent_app_number] => 10373579 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 411102 [patent_doc_number] => 07282198 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2007-10-16 [patent_title] => 'Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme' [patent_app_type] => utility [patent_app_number] => 10/372521 [patent_app_country] => US [patent_app_date] => 2003-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 37 [patent_no_of_words] => 13933 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 119 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/282/07282198.pdf [firstpage_image] =>[orig_patent_app_number] => 10372521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 609744 [patent_doc_number] => 07151164 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-12-19 [patent_title] => 'Anti-CD20 antibodies and fusion proteins thereof and methods of use' [patent_app_type] => utility [patent_app_number] => 10/366709 [patent_app_country] => US [patent_app_date] => 2003-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 26180 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/151/07151164.pdf [firstpage_image] =>[orig_patent_app_number] => 10366709 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 695824 [patent_doc_number] => 07071311 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-07-04 [patent_title] => 'Antibodies having specificity for 2′-C-allyl nucleic acids' [patent_app_type] => utility [patent_app_number] => 10/366191 [patent_app_country] => US [patent_app_date] => 2003-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 17628 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/071/07071311.pdf [firstpage_image] =>[orig_patent_app_number] => 10366191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6739722 [patent_doc_number] => 20030157091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-08-21 [patent_title] => 'Multi-functional proteins' [patent_app_type] => new [patent_app_number] => 10/364815 [patent_app_country] => US [patent_app_date] => 2003-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23485 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0157/20030157091.pdf [firstpage_image] =>[orig_patent_app_number] => 10364815 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6701517 [patent_doc_number] => 20030224397 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-12-04 [patent_title] => 'Antibody variants with faster antigen association rates' [patent_app_type] => new [patent_app_number] => 10/364953 [patent_app_country] => US [patent_app_date] => 2003-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 21937 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0224/20030224397.pdf [firstpage_image] =>[orig_patent_app_number] => 10364953 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7405677 [patent_doc_number] => 20040175786 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2004-09-09 [patent_title] => 'Anti-cd3 single-chain antibodies having human cmu3 and cmu4 domains' [patent_app_type] => new [patent_app_number] => 10/181305 [patent_app_country] => US [patent_app_date] => 2003-02-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 6040 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0175/20040175786.pdf [firstpage_image] =>[orig_patent_app_number] => 10181305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6710481 [patent_doc_number] => 20030170230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-09-11 [patent_title] => 'Compositions and methods for assembly and stabilization of antibody Fv fragments via antiparallel heterogeneous coiled-coil peptide regions and uses thereof' [patent_app_type] => new [patent_app_number] => 10/360053 [patent_app_country] => US [patent_app_date] => 2003-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 6789 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0170/20030170230.pdf [firstpage_image] =>[orig_patent_app_number] => 10360053 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6770382 [patent_doc_number] => 20030216322 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-11-20 [patent_title] => 'Peptides for recognition and targeting of GLIAL cell tumors' [patent_app_type] => new [patent_app_number] => 10/357929 [patent_app_country] => US [patent_app_date] => 2003-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15341 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0216/20030216322.pdf [firstpage_image] =>[orig_patent_app_number] => 10357929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6701584 [patent_doc_number] => 20030224464 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-12-04 [patent_title] => 'Secreted caveolin as a marker for prostate cancer' [patent_app_type] => new [patent_app_number] => 10/355259 [patent_app_country] => US [patent_app_date] => 2003-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 7862 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0224/20030224464.pdf [firstpage_image] =>[orig_patent_app_number] => 10355259 [rel_patent_id] =>[rel_patent_doc_number] =>)